SynthesisBMC oral health2025
Efficacy of duloxetine in treating temporomandibular joint disorder: a systematic review with bayesian meta-analysis.
Synthesis in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aims to evaluate the efficacy of duloxetine in managing temporomandibular joint disorder (TMD), focusing on pain reduction and functional improvement. The research addresses the need for novel therapeutic agents due to the suboptimal efficacy and tolerability of existing treatments. MATERIALS AND
methodsA systematic review and Bayesian meta-analysis were conducted following PRISMA guidelines. A comprehensive search of MEDLINE (via PubMed), Web of Science, Scopus, Embase, and Google Scholar was performed up to February 2025. Eligibility criteria were defined using the PICOS framework: Population (TMD patients), Intervention (duloxetine), Comparator (placebo or other treatments), Outcomes (pain reduction, maximum mouth opening), and Study design (randomized controlled trials). Data synthesis employed Bayesian meta-analysis, and evidence quality was assessed using the GRADE framework.
resultsFive studies involving 203 participants met the inclusion criteria. Four evaluated duloxetine combined with TMJ arthrocentesis, while one compared duloxetine to a placebo. Combination therapy yielded significant pain reduction (pooled effect size = 1.42) and a consistent, though not statistically significant, improvement in maximum mouth opening. Bayesian analysis strongly supported pain reduction (BF
conclusionDuloxetine, when combined with TMJ arthrocentesis, provides significant pain relief and potential functional benefits in TMD management. However, further large-scale, high-quality randomized trials are necessary to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.